Proteovista LLC

Madison, WI · Biotech · Private

GenomeBuild, a method to synthesize complete viral genomes rapidly and inexpensively from DNA microarray-derived oligonucleotides

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · proteovista.com

Sector: Biotech
Headquarters: Madison, WI
Total capital: $2.7M

Federal grants: $2.1M; 7 awards · 2016–2026; Rank in peer group#27 of 79
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $600K; 1 award · Health and Human S; Rank in Biotech#217 of 4373
Granted patents: 1; 1 pending · first 2020; Rank in peer group#23 of 79

Capital timeline

Latest events

Jun 2026Federal grantHealth and Human S · Phase I · Development of ClusterBuild to Synthesize Biosynthetic Gene Clusters$306K
Mar 2023Federal grantHealth and Human S · Phase I · Development of GenomeBuild as a Universal Method to Synthesize Genomes$377K
Mar 2023Federal grantHealth and Human S · Phase I · Development of GenomeBuild as a Universal Method to Synthesize Genomes$377K
Aug 2021Federal contractHealth and Human S · Development Of Aptamers To Recognize Nod-like Receptors In Zebrafish$600K
Sep 2019Federal grantHealth and Human S · Phase I · Development of the High Throughput APT-SNAP Platform for Rapid Identification ofNuclease-Resistant RNA Aptamers against p53 Missense Mutations$225K
Sep 2019Federal grantHealth and Human S · Phase I · Development of the High Throughput APT-SNAP Platform for Rapid Identification ofNuclease-Resistant RNA Aptamers against p53 Missense Mutations$225K
Aug 2018Federal grantHealth and Human S · Phase I · Site-Specific Incorporation of Phosphorylation Modifications on the SNAP-Tide High Density Peptide Array$223K

Show 1 earlier federal award

May 2016Federal grantHealth and Human S · Phase I · Aptamer-Based Detection of Cardiac Biomarker Glycosylation States Using APT-SNAP$326K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 79 peers

Line = median

Biotech · System

Federal grants#27 · top 34%
Granted patents#23 · top 29%
Linked publications#5 · top 6%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 2

Dec 1, 2020GrantedSnp ArraysUSPTOUS 10,851,423
PendingSnp ArraysUSPTOApplication PCTUS2016038399

Recent research by its founders

Defining the DNA Binding Specificity of GRHL220260 cites
Elevated GRHL2 Imparts Plasticity in ER-Positive Breast Cancer Cells20243 cites
7615 Genomic Consequences of GRHL2 Overexpression in ER+ Breast Cancer Cells20240 cites

Perfinity Biosciences, Inc.Similar federal contract value in Biotech · $649K in contracts
iXpressGenes, Inc.Similar federal contract value in Biotech · $614K in contracts
NEUCYTE INCSimilar federal contract value in Biotech · $602K in contracts
TEICHOS LABORATORIES, LLCSimilar federal contract value in Biotech · $600K in contracts
TENDEL THERAPIES INCSimilar federal contract value in Biotech · $600K in contracts
EVIMERO, LLCSimilar federal contract value in Biotech · $597K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.